Medical Oncology

Jeffrey Melson Clarke, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept Of Medicine, Box_31379 Med Ctr, Durham, NC 27710
Phone (919) 684-8111
Email address jeffrey.clarke@duke.edu
In Their Words

Education and Training

  • Internal Medicine Chief Resident, Medicine, Duke University School of Medicine, 2012 - 2013
  • Hematology and Medical Oncology Fellowship, Medicine, Duke University School of Medicine, 2011 - 2015
  • Categorical Internal Medicine Residency, Medicine, Duke University School of Medicine, 2008 - 2011
  • M.D., Indiana University School of Medicine, 2008

Grants

Publications

Clarke, JM, George, DJ, Lisi, S, and Salama, AKS. "Immune Checkpoint Blockade: The New Frontier in Cancer Treatment." Targeted oncology 13, no. 1 (February 13, 2018): 1-20.

PMID
29441437
Full Text

Yi, JS, Ready, N, Healy, P, Dumbauld, C, Osborne, R, Berry, M, Shoemaker, D, Clarke, J, Crawford, J, Tong, B, Harpole, D, D'Amico, TA, McSherry, F, Dunphy, F, McCall, SJ, Christensen, JD, Wang, X, and Weinhold, KJ. "Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23, no. 24 (December 2017): 7474-7482.

PMID
28951518
Full Text

Bedoya, A, Glisinski, K, Clarke, J, Lind, RN, Buckley, CE, and Shofer, S. "Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases." The American Journal of Case Reports 18 (July 31, 2017): 842-846.

PMID
28757601
Full Text

Clarke, JM, Wang, X, and Ready, NE. "Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?." Translational lung cancer research 4, no. 6 (December 2015): 804-808.

PMID
26798592
Full Text

Hatch, AJ, Clarke, JM, Nixon, AB, and Hurwitz, HI. "Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress." Cancer journal (Sudbury, Mass.) 21, no. 4 (July 2015): 322-326. (Review)

PMID
26222085
Full Text

Lyman, GH, Bohlke, K, Khorana, AA, Kuderer, NM, Lee, AY, Arcelus, JI, Balaban, EP, Clarke, JM, Flowers, CR, Francis, CW, Gates, LE, Kakkar, AK, Key, NS, Levine, MN, Liebman, HA, Tempero, MA, Wong, SL, Somerfield, MR, Falanga, A, and American Society of Clinical Oncology, . "Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 6 (February 2015): 654-656.

PMID
25605844
Full Text

Clarke, JM, Hurwitz, HI, and Rangwala, F. "Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective." Cancer treatment reviews 40, no. 9 (October 2014): 1065-1072. (Review)

PMID
25047778
Full Text

Clarke, JM, Hurwitz, HI, and Rangwala, F. "Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician's perspective." Cancer Treatment Reviews 40, no. 9 (2014): 1065-1072.

Full Text

Clarke, JM, and Hurwitz, HI. "Understanding and targeting resistance to anti-angiogenic therapies." J Gastrointest Oncol 4, no. 3 (September 2013): 253-263.

PMID
23997938
Full Text

Clarke, JM, and Hurwitz, HI. "Targeted inhibition of VEGF receptor 2: an update on ramucirumab." Expert Opinion on Biological Therapy 13, no. 8 (August 2013): 1187-1196. (Review)

PMID
23803182
Full Text

Pages